Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-915 PET Occupancy Study
NCT02584569Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAK-915 in schizophrenia, sponsored by Takeda. Primary endpoint: Phosphodiesterase 2A Brain Enzyme Occupancy in the Putamen at Day 2. Started Nov 2015; status: completed.
02
Drugs
TAK-915
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02584569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584569.